Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

NCT02203643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

477

Enrollment

OTHER

Sponsor class

Conditions

MULTIPLE MYELOMA (MM)

Interventions

DRUG: Carfilzomib
DRUG: Cyclophosphamide
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Mario Boccadoro